X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	185.8	217.05	55.7	99.22	121.72	81.79
Short-Term Investments	1.9	35.95	46.36	15	-	-
Cash & Short-Term Investments	187.7	253	102.06	114.22	121.72	81.79
Cash Growth	53.61%	147.89%	-10.64%	-6.16%	48.82%	3.91%
Accounts Receivable	1.47	0.57	1.07	-	-	-
Other Receivables	-	-	0.64	0.56	1.15	0.75
Receivables	1.47	0.57	1.71	0.56	1.15	0.75
Inventory	5.51	4.48	2.82	-	-	-
Prepaid Expenses	2.88	2.52	5.59	7.05	5.52	5.34
Restricted Cash	0.58	0.8	-	0.25	0.29	-
Other Current Assets	-	0.2	-	-	-	-
Total Current Assets	198.13	261.58	112.18	122.08	128.68	87.88
Property, Plant & Equipment	0.32	1.59	4.84	6.4	8.33	10.22
Goodwill	17.35	17.35	17.35	17.35	17.35	17.35
Other Intangible Assets	12.82	9.25	10	-	-	-
Long-Term Deferred Charges	-	0.5	-	-	-	-
Other Long-Term Assets	3.19	0.19	2.08	1.44	1.23	1.72
Total Assets	231.82	290.46	146.45	147.26	155.59	117.18

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.88	5.7	8.62	8.95	7.78	4.28
Accrued Expenses	8.77	18.6	23.01	12.82	11.44	7.85
Current Portion of Long-Term Debt	-	-	-	-	1.32	0.8
Current Portion of Leases	0.19	0.99	1.25	1.1	1.2	1.08
Current Unearned Revenue	0.94	0.46	-	-	-	-
Other Current Liabilities	0.21	-	-	-	0.59	0.03
Total Current Liabilities	14.98	25.76	32.88	22.86	22.32	14.02
Long-Term Debt	77.01	76.29	75.43	54.57	32.3	33.14
Long-Term Leases	-	-	1.41	2.61	3.6	4.78
Long-Term Unearned Revenue	0.39	0.62	-	-	-	-
Other Long-Term Liabilities	0.55	1.5	14.59	16.12	23.3	0.83
Total Liabilities	92.93	104.17	124.3	96.16	81.54	52.76

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.1	0.09	0.01	0.17	0.12	0.03
Additional Paid-In Capital	789.93	780.86	537.62	528.96	450.79	347.37
Retained Earnings	-651.15	-594.55	-515.36	-477.91	-376.74	-282.87
Comprehensive Income & Other	-	-0.11	-0.12	-0.12	-0.12	-0.12
Total Common Equity	138.88	186.29	22.15	51.1	74.05	64.41
Shareholders' Equity	138.88	186.29	22.15	51.1	74.05	64.41
Total Liabilities & Equity	231.82	290.46	146.45	147.26	155.59	117.18

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	77.2	77.29	78.09	58.28	38.42	39.79
Net Cash (Debt)	110.51	175.71	23.97	55.94	83.3	42
Net Cash Growth	146.46%	632.93%	-57.14%	-32.85%	98.32%	4.33%
Net Cash Per Share	0.90	4.15	3.58	9.44	39.34	48.94
Filing Date Shares Outstanding	102.11	90.92	5.79	5.6	4.07	1.03
Total Common Shares Outstanding	100.9	90.91	5.7	5.58	4.06	0.94
Working Capital	183.15	235.82	79.3	99.21	106.35	73.86
Book Value Per Share	1.38	2.05	3.89	9.16	18.26	68.70
Tangible Book Value	108.71	159.69	-5.2	33.75	56.7	47.06
Tangible Book Value Per Share	1.08	1.76	-0.91	6.05	13.98	50.19
Machinery	1.22	1.19	2.43	2.11	2.08	1.98
Leasehold Improvements	0.23	0.23	0.23	0.23	0.23	0.23

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error